Eli Lilly & Co.: Insider Transactions, Governance Networks, and Strategic Affiliations

An examination of Eli Lilly and Company (NYSE: LLY) through its regulatory filings—specifically its definitive proxy statement (Form DEF 14A filed March 20, 2026), its Annual Report (Form 10-K for the fiscal year ended December 31, 2025), and recent SEC Form 4 insider transaction reports—reveals a clear governance, commercial, and executive network spanning global mega-caps, platform biotechnology companies, and technology infrastructure partners.

---

Eli Lilly Fundamental and Capital Structure Baseline

Before evaluating insider activity, we must contextualize the scale and market expectations embedded in Eli Lilly:

• Valuation Snapshot (November 2026): Trading around $1,427 per share, Eli Lilly commands a market capitalization of $1.33 trillion. The stock trades at approximately 48.2 times trailing twelve-month earnings, pricing in exceptional durability and market dominance across its cardiometabolic franchise (tirzepatide / Mounjaro / Zepbound) and its clinical pipeline (such as the oral GLP-1 receptor agonist orforglipron and next-generation amylin agonist eloralintide).
• Audited Operating Performance (Fiscal 2025):
  • Revenue: $65.18 billion, up 44.7% from $45.04 billion in 2024 and 91.0% from $34.12 billion in 2023.
  • Net Income: $20.64 billion, delivering a net margin of 31.7%.
  • Capital Returns: Return on invested capital (ROIC) stands at 36.1%, return on capital at 35.3%, and gross margin at 83.0%.
  • Balance Sheet Health: Cash reserves totaled $7.27 billion against a total debt-to-EBITDA ratio of 1.50x (net debt-to-EBITDA of 1.25x), giving management substantial financial headroom to fund clinical trials and capital investments internally.

---

Analysis of Insider Transactions at Eli Lilly

Form 4 filings over the six-month period ending November 2026 show that insider activity at Lilly has been characterized primarily by routine tax-withholding share surrender upon restricted stock unit (RSU) vesting, alongside selective open-market sales. There have been no open-market purchases by named executive officers.

1. Named Executive Officers (Form 4 Filings)

• David A. Ricks (Chair, President, and CEO):
  • Transaction: On November 3, 2026, disposed of 23,538 shares at $0.00 (tax withholding / share change upon vesting).
  • Total Beneficial Ownership: As reported in the 2026 DEF 14A, Ricks directly and indirectly holds significant equity, including 106,693 shares held via a family foundation for which he serves as director. Under his leadership since 2017, Lilly has compounded revenues by over 200%.
• Anat Hakim (EVP, General Counsel and Secretary):
  • Transaction: On November 2, 2026, executed an open-market sale of 5,000 shares at an average price of $1,402.52 per share, realizing approximately $7.01 million.
  • Context: As chief legal officer, Hakim oversees Lilly’s enterprise risk, patent defense, and active enforcement litigation against compounding pharmacies and counterfeiting rings targeting tirzepatide.
• Patrik Jonsson (Executive Officer):
  • Transaction: On August 17, 2026, executed an open-market sale of 6,500 shares at $1,175.10 per share, realizing approximately $7.64 million.
• Daniel Skovronsky, M.D., Ph.D. (EVP, Chief Scientific and Product Officer, President of Lilly Research Laboratories):
  • Transaction: On November 2, 2026, disposed of 119 shares at $0.00 for tax withholding. Dr. Skovronsky has spent 15 years at Lilly, directing R&D execution across oncology, immunology, and metabolic disease.
• Adrienne S. Brown (EVP and President, Lilly Immunology):
  • Transactions: On November 1, 2026, acquired 2,530 shares via RSU vesting, with 1,099 shares withheld for taxes at $1,417.54 per share (transaction value: ~$1.56 million), and a net share change of 2,530 shares.
• Kenneth L. Custer, Ph.D. (EVP and President, Lilly Cardiometabolic Health):
  • Transactions: On November 1, 2026, acquired 3,220 shares via RSU vesting, with 1,425 shares withheld for taxes at $1,417.54 per share (transaction value: ~$2.02 million), and a net share change of 3,220 shares.
• Eric Dozier (EVP, Chief People Officer):
  • Transactions: On November 1, 2026, acquired 2,300 shares via RSU vesting, with 1,019 shares withheld for taxes at $1,417.54 per share (transaction value: ~$1.44 million), and a net share change of 2,300 shares. Earlier on September 2, 2026, disposed of 216 shares at $0.00.

2. Non-Employee Directors (Automatic Deferrals / Phantom Shares)

Between September and October 2026, several independent directors received routine monthly equity credits pursuant to the Lilly Directors’ Deferral Plan at prices between $1,164.89 and $1,240.34 per share:

• Juan R. Luciano: +14 shares (Sept. 21) and +13 shares (Oct. 19).
• Ralph Alvarez: +11 shares (Sept. 21) and +10 shares (Oct. 19).
• J. Erik Fyrwald: +9 shares (Sept. 21) and +8 shares (Oct. 19).
• Gabrielle Sulzberger: +4 shares (Sept. 21) and +4 shares (Oct. 19).

These micro-allocations reflect non-discretionary director retainer compensation rather than active market bets.

---

Mapping the Public Company Network

Lilly’s board of directors, executive committee, and major shareholders create structural links to several major public corporations:

                          ┌──────────────────────────┐
                          │   ELI LILLY & CO (LLY)   │
                          └─────────────┬────────────┘
                                        │
     ┌──────────────────┬───────────────┼───────────────┬──────────────────┐
     │                  │               │               │                  │
┌────┴───────┐   ┌──────┴─────┐   ┌─────┴──────┐  ┌─────┴──────┐   ┌───────┴──────┐
│  Biotech & │   │ Corporate  │   │  Consumer  │  │ Institutional│ │ Tech & Compute│
│   Pharma   │   │ Leadership │   │ & Ag/Ind.  │  │ & Banking  │ │ Partnerships │
└────┬───────┘   └──────┬─────┘   └─────┬──────┘  └─────┬──────┘   └───────┬──────┘
     │                  │               │               │                  │
     ├► OmniAb          ├► Biogen       ├► P&G          ├► Lilly Endowment └► NVIDIA
     │  (OABI)          │  (BIIB)       │  (PG)         │  (9.8% stake)       (NVDA)
     │                  │               │               │
     ├► Alnylam         └► Loxo         ├► ADM          ├► Vanguard
     │  (ALNY)             Oncology     │  (ADM)        │  (8.6% stake)
     │                     (Acquired)   │               │
     └► Pfizer / Merck                  └► Syngenta /   ├► BlackRock
        (Commercial Peers)                 International│  (6.8% stake)
                                           Flavors      │
                                                        └► PNC Financial
                                                           (5.4% stake)

1. Biotechnology and Translational Medicine

• OmniAb, Inc. (NASDAQ: OABI) & Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY):
  • The Insider: Carolyn R. Bertozzi, Ph.D. (Nobel Laureate in Chemistry; Lilly Director since 2025; member of Ethics and Compliance, and Science and Technology Committees).
  • Connection: Dr. Bertozzi serves on the board of OmniAb, an antibody discovery platform company. She also previously served on the board of RNA interference (RNAi) pioneer Alnylam Pharmaceuticals.
  • Significance: Dr. Bertozzi’s board presence links Lilly directly to high-throughput discovery platforms. As large pharmaceutical portfolios seek next-generation biologics to replace impending patent cliffs, her presence provides Lilly’s Science and Technology committee with direct scientific oversight of platform technologies that supply drug candidates across the biopharma sector.

2. Corporate Governance, Supply Chains, and Consumer Goods

• The Procter & Gamble Company (NYSE: PG):

  • The Insider: Jon R. Moeller (Lilly Director since 2024; member of Audit and Directors and Corporate Governance Committees).
  • Connection: Moeller served as President and CEO of Procter & Gamble from 2021 to 2025, Chairman from 2022 to 2025, and assumed the role of Executive Chairman of P&G in 2026.
  • Significance: Lilly’s commercial pivot involves scaling massive direct-to-consumer operations via LillyDirect, which now reaches over 1 million patients. P&G represents the gold standard in global consumer packaging, brand loyalty, direct-to-consumer distribution, and retail supply-chain management. Moeller's dual presence connects pharmaceutical manufacturing scale with consumer-grade marketing and distribution governance.

• Archer-Daniels-Midland Company (NYSE: ADM):

  • The Insider: Juan R. Luciano (Lilly Director; Chair of Directors and Corporate Governance Committee).
  • Connection: Luciano is the Chairman and CEO of agricultural processing and nutrition giant ADM.
  • Significance: Offers board-level insight into industrial-scale fermentation, bio-processing, and global commodity supply logistics, which are increasingly vital as peptide synthesis scales to global agricultural-sized procurement tiers.

3. Cross-Pharma Executive Talent Pipelines

• Biogen Inc. (NASDAQ: BIIB):

  • The Insider: Melissa Seymour (EVP, Global Quality at Lilly).
  • Connection: As noted in Lilly's Form 10-K, prior to joining Lilly, Seymour served as Chief Quality Officer at Biogen.
  • Significance: Lilly and Biogen have navigated high-stakes neuroscience and immunology manufacturing hurdles, particularly around monoclonal antibodies targeting amyloid-beta plaques in Alzheimer's (Lilly’s donanemab / Kisunla vs. Biogen/Eisai’s lecanemab / Leqembi). Executive movement in technical quality and regulatory compliance reflects the high demand for specialized biologic manufacturing oversight.

• Loxo Oncology (Acquired Asset Integration):

  • The Insider: Jacob Van Naarden (EVP, President of Lilly Oncology and Head of Corporate Business Development).
  • Connection: Van Naarden previously served as CEO and COO of Loxo Oncology, which Lilly acquired in 2019 for $8.0 billion. He also spent time in venture investing at Aisling Capital and HealthCor Management.
  • Significance: Van Naarden is Lilly’s primary architect for oncology M&A and corporate development. The success of Loxo assets (such as pirtobrutinib / Jaypirca, which recently gained European approvals for CLL) has turned Van Naarden into Lilly's primary capital allocator for biotech licensing, partnership evaluation, and targeted acquisitions.

4. Technology and Advanced Compute Partnerships

• NVIDIA Corporation (NASDAQ: NVDA):
  • The Connection: As disclosed in the 2026 DEF 14A under executive compensation highlights, Lilly established an NVIDIA AI supercomputer partnership alongside the launch of its "TuneLab" platform for AI-enabled molecular discovery.
  • Significance: Lilly is deploying dedicated high-performance compute clusters to accelerate structural biology simulations and generative small-molecule design, cementing an infrastructure tie between the world's most valuable semiconductor designer and the world's most valuable pharmaceutical manufacturer.

---

Major Institutional Shareholders: The 5% Holders

Lilly’s Form DEF 14A identifies four entities holding more than 5% of its common stock:

| Shareholder | Shares Held | Percent of Class | Nature of Ownership / Control | | :--- | :--- | :--- | :--- | | Lilly Endowment Inc. | 92,190,516 | 9.8% | Sole voting and investment power. Historic foundation anchor; long-term stable ownership with zero takeover vulnerability. | | The Vanguard Group | 80,952,595 | 8.6% | Passive indexation and institutional asset management. | | BlackRock, Inc. | 64,376,027 | 6.8% | Passive indexation and institutional asset management. | | The PNC Financial Services Group, Inc. | 51,153,837 | 5.4% | Fiduciary asset management and regional banking custody. |

The combined holdings of the Lilly Endowment, Vanguard, BlackRock, and PNC represent 30.6% of Lilly’s outstanding common stock. The 9.8% stake held by the Lilly Endowment provides an exceptional corporate governance shield, allowing executive leadership to make 10- to 15-year R&D capital commitments without fear of short-term activist interference.

---

The 10 Most Interesting Connected Companies

Evaluating the corporate, scientific, and governance ties revealed through Lilly’s filings highlights ten publicly traded companies worthy of investment analysis:

1. OmniAb, Inc. (NASDAQ: OABI)

• The Connection: Lilly Director Dr. Carolyn Bertozzi serves on OmniAb's board of directors.
• Why It Matters: OmniAb operates a high-margin biological discovery platform using transgenic animal systems to generate fully human antibodies. Bertozzi’s scientific validation is an endorsement of their discovery engine.
• Investment Relevance: Deserves deeper fundamental research as an asset-light, royalty-bearing biotechnology platform that benefits from broader industry R&D spending without carrying primary clinical trial binary risk.

2. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

• The Connection: Former board directorship of Dr. Carolyn Bertozzi; shared technological frontier in liver-targeted RNA interference.
• Why It Matters: As the cardiometabolic race moves from daily/weekly injections toward durable, infrequent siRNA gene silencing (targeting LPA, PCSK9, and ANGPTL3), Alnylam remains the foundational platform owner.
• Investment Relevance: Deserves close tracking. If large pharmaceutical players seek to acquire long-acting siRNA cardiometabolic assets to complement GLP-1/GIP franchises, Alnylam is a central strategic asset.

3. The Procter & Gamble Company (NYSE: PG)

• The Connection: Board overlap via Jon R. Moeller (P&G Executive Chairman and Lilly Director).
• Why It Matters: Reflects governance alignment between elite operational capital allocators. Moeller brings P&G’s supply chain efficiency and consumer pricing discipline to Lilly as it expands direct-to-consumer operations (LillyDirect).
• Investment Relevance: P&G is a mature compounder rather than a discovery biotech, but the connection validates Lilly’s operational pivot toward treating chronic disease therapies with the supply reliability of consumer consumer staples.

4. NVIDIA Corporation (NASDAQ: NVDA)

• The Connection: Direct operational partnership disclosed in Lilly’s executive compensation filings to power Lilly’s AI-enabled drug design platform (TuneLab).
• Why It Matters: Illustrates that sovereign-scale AI infrastructure is being adopted by cash-rich pharmaceutical leaders to compress discovery cycles from years to months.
• Investment Relevance: Deserves continual evaluation not merely as a tech trade, but as a core infrastructure beneficiary of pharmaceutical R&D balance-sheet deployment.

5. Biogen Inc. (NASDAQ: BIIB)

• The Connection: Executive talent pipeline (Lilly’s EVP of Global Quality Melissa Seymour was Biogen’s Chief Quality Officer); direct clinical competition in neurodegenerative disease.
• Why It Matters: Both companies are navigating the commercialization and manufacturing scale-up of anti-amyloid monoclonal antibodies (Kisunla vs. Leqembi).
• Investment Relevance: Requires monitoring on whether Biogen’s compressed multiple adequately discounts its dependence on partner Eisai, whereas Lilly’s superior balance sheet enables it to out-invest Biogen in Alzheimer's commercial infrastructure.

6. Archer-Daniels-Midland Company (NYSE: ADM)

• The Connection: Board governance link via Juan R. Luciano (ADM Chair/CEO and Lilly Lead Independent Director).
• Why It Matters: Luciano leads Lilly's governance committee. ADM’s operational challenges and expertise in global agricultural bio-refining provide valuable case studies in cost-structure containment for large fermentation-based manufacturing operations.
• Investment Relevance: A cyclical industrial turnaround rather than a biopharma play; not directly complementary to Lilly’s investment case, but valuable for tracking bio-processing input costs.

7. The PNC Financial Services Group, Inc. (NYSE: PNC)

• The Connection: Disclosed 5.4% institutional holder of Eli Lilly (51.15 million shares), representing a multi-billion-dollar balance-sheet and trust asset concentration.
• Why It Matters: PNC holds a significant, historical fiduciary custody role in Lilly stock, acting as a regional banking anchor alongside the Lilly Endowment.
• Investment Relevance: Deserves research as a conservatively capitalized regional bank whose wealth management and fiduciary custody divisions benefit directly from fee expansion linked to the compounding market capitalization of legacy industrial clients like Lilly.

8. Viking Therapeutics, Inc. (NASDAQ: VKTX)

• The Connection: Competitive shadow over Lilly’s cardiometabolic pipeline. Highlighted in recent market intelligence as a dual GLP-1/GIP agonist challenger.
• Why It Matters: Lilly raised its fiscal 2026 sales forecast toward $92 billion, driven by tirzepatide demand. Viking’s Phase 2/3 oral and subcutaneous data represent the primary competitive risk to Lilly and Novo Nordisk's duopoly.
• Investment Relevance: Deserves high-priority research to assess whether Viking represents an attractive acquisition target for an LOE-threatened peer (such as Merck, Pfizer, or Bristol Myers Squibb) or a standalone challenger that could erode Lilly’s terminal pricing power.

9. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

• The Connection: Peer cash-funded orphan drug model; commercial counterparty dynamic in rare disease acquisitions.
• Why It Matters: Lilly’s corporate business development group (under Jake Van Naarden) routinely scans for cash-flow-accretive, de-risked orphan platforms that are insulated from broader patent cliffs.
• Investment Relevance: With an audited ROIC of 23.1%, zero debt, and high cash-flow margins on Firdapse, Catalyst illustrates the exact profile of a self-funding orphan biotech that large pharmaceutical balance sheets look to bolt on to diversify beyond primary care blockbusters.

10. Novo Nordisk A/S (NYSE: NVO)

• The Connection: Structural commercial duopolist. Every trial result reported in Lilly’s proxy (e.g., the SURMOUNT-5 head-to-head trial where Zepbound showed 20.2% weight loss vs. Wegovy’s 13.7%) benchmarks directly against Novo.
• Why It Matters: The GLP-1/GIP market is not a zero-sum game today due to global supply shortages, but terminal economics will be governed by manufacturing yield advantages, supply-chain scale, and next-generation oral formulations (orforglipron vs. oral semaglutide / amycretin).
• Investment Relevance: High priority. An investor cannot establish a high-conviction valuation for Eli Lilly without simultaneously stress-testing Novo Nordisk’s manufacturing capex investments and pipeline parity.

---

Key Takeaway for Capital Allocation

The insider network at Eli Lilly reveals an executive suite focused on locking down three strategic moats:

1. Supply-chain and consumer scale (via directors from Procter & Gamble and ADM to manage global distribution and manufacturing).
2. Next-generation biological platforms (via scientific leaders connected to Alnylam and OmniAb to secure post-tirzepatide discovery pipelines).
3. Advanced computational infrastructure (partnering directly with NVIDIA to lower drug candidate discovery costs).

With the stock trading at 48.2x earnings, Lilly's fundamental bar for execution is set extraordinarily high. The insider trading activity—characterized by a lack of open-market buying and selective multi-million-dollar executive sales—suggests that while leadership is executing flawlessly on operations, the market price has already captured a significant portion of the near-term cash-flow expansion.